The unique tumor - tropic properties of neural stem cells (NSCs) may provide the means to significantly improve antibody distribution within
metastatic tumor sites throughout the body [2], [3], [4], [5], [6].
Intravenously - delivered NSCs preferentially migrate to primary and
metastatic tumor sites within and outside the CNS.
Not exact matches
Plasma samples also can not address the issue of expression heterogeneity (primary
tumor vs.
metastatic site (s)-RRB-.
«The recent discovery of
tumor - promoting milieus, referred to as
metastatic niches, that are established at distant
sites prior to or upon the arrival of disseminated
tumor cells could explain cancer cells that relapse early, but in late relapsing populations, what
tumor cells do from the time of dissemination to the time they become clinically detectable has been a big question.»
The team chose to compare breast tissue from healthy individuals with
tumor samples taken from breast cancer patients — including both primary
tumors that had not spread from the breast to other body
sites, and highly aggressive,
metastatic tumors.
In some individuals there were significant genetic differences between
tumor sites, suggesting early
metastatic spread; in others, there was little difference between a primary
tumor and its metastases.
It is not easy to determine whether metastasis began early or late in the development of the primary
tumor or whether individual
metastatic sites were seeded directly from the original
tumor or from an intermediate
site.
«Given the high discrepancy of genetic findings between a primary
tumor and
metastatic sites within the same patient, our study suggests we should concentrate on
metastatic sites that represent the majority of the
tumor burden.
The prognosis for
metastatic cancer (also called stage IV cancer) is generally poor, so a technique that could detect these circulating
tumor cells before they have a chance to form new colonies of
tumors at distant
sites could greatly increase a patient's survival odds.
However,
metastatic tumors continued to appear over time in untreated
sites likely because those
tumors were so small at initial treatment that they were not detected.
After first verifying that stem cells injected to the brain would travel to multiple
metastatic sites and not to
tumor - free areas in their model, the team injected stem cells loaded with oHSV into the carotid artery of metastasis - bearing mice..
hen breast cancer patients get chemotherapy before surgery to remove their
tumor, it can make remaining malignant cells spread to distant
sites, resulting in incurable
metastatic cancer, scientists reported last week.
The degree of heterogeneity did not differ between primary and
metastatic sites, indicating that more than one core biopsy, or even an entire
tumor block might be needed to determine PD - L1 expression in a
tumor.
Tissue heterogeneity in PD - L1 expression in both primary and
metastatic sites indicates that a single core biopsy might not be sufficient to determine
tumor PD - L1 expression.
One limitation of our study is the use of
metastatic samples from various organ
sites, potentially influencing expression via differences from the organ - specific
tumor microenvironment.
While
metastatic sites may have originated from the primary
tumor, several studies have demonstrated a different immunohistochemical or mutation profile compared to the primary.
currently the
tumor treatment studies are restricted to primary
tumors but very little is being done to understand nanoparticle routing and penetration of
metastatic site
[25] Seeing that in
metastatic patients the only available
tumor is often core biopsies rather than whole tissue blocks, we next attempted to determine whether the degree of heterogeneity varies between primary and
metastatic sites, using the TMA cores as surrogates for core biopsy specimens.
Within a given
tumor, variable PD - L1 staining heterogeneity was seen, however the degree of heterogeneity was similar in primary and
metastatic sites (P = 0.482).
Additionally there is only weak correlation in staining between the matched primary and distant metastasis, suggesting that the primary
tumor is not an adequate surrogate for determining PD - L1 expression in
metastatic sites.
There was no difference in lactate dehydrogenase, the number of
metastatic sites, prior adjuvant therapy, primary in place at initiation of therapy, or intent of treatment across the cohorts for right - compared with left - sided
tumors.
MCG / AU Health was the only
site for the phase 1 trial to test the vaccine's safety and look at
tumor response in patients with persistent, recurrent and / or
metastatic disease.
Metastatic disease refers to cancer that has spread through the blood or lymph system to form new
tumors in other parts of the body distinct from the original
site.
December 13, 2011 Molecular markers can predict spread of cancer, guide treatment Molecular markers found in cancer cells that have spread from a primary
tumor to a limited number of distant
sites can help physicians predict which patients with
metastatic cancer will benefit from aggressive, targeted radiation therapy.
This is supported by recently published data in the New England Journal of Medicine (21), where patients with triple - negative breast cancer were seen to show increased complete pathologic response to bevacizumab treatment, with no detectable
tumor at primary or
metastatic sites, whereas no improvement was observed in hormone receptor — positive cases.
The
tumors are very aggressive and
metastatic, so it is a fair assumption that at the time of diagnosis the disease will have already spread beyond the primary
site.
We believe that disrupting this niche will delay or prevent
metastatic spread, and more importantly, protect
tumor sites from hemorrhage, which is the most common lethal event in this disease.
Hematogenous
metastatic brain
tumors commonly originate from extracranial
sites.